文献速递白血病造血干细胞移植与细胞治疗

PASS-ALL研究:儿童启发方案与成人化疗方案对高危费城染色体阴性B细胞急性淋巴细胞白血病异基因造血干细胞移植生存的影响

PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
PubMed 文献 · Br J Haematol · 2023-12-05

PASS-ALL为多中心观察性队列研究,纳入5个中心143例适合异基因造血干细胞移植的高危费城染色体阴性B细胞急性淋巴细胞白血病患者,其中77例接受儿童启发方案、66例接受成人方案,128例实际接受移植。儿童启发队列3年无白血病生存率72.2%,高于成人队列44.6%(p=0.001);3年累积复发率儿童启发队列25.9%,低于成人队列45.4%(p=0.026);3年总生存率两组分别为75.3%与64.1%(p=0.074)。

要点

  • 儿童启发方案组3年无白血病生存率72.2%,成人方案组44.6%(p=0.001)
  • 儿童启发方案组3年累积复发率25.9%,成人方案组45.4%(p=0.026)
  • 多因素分析儿童启发方案为无白血病生存的预测因素(HR=2.540,95%CI 1.327-4.862,p=0.005)

核心结论

  • 数据提示移植前儿童启发化疗可获得更深、更持久的微小残留病反应,减少移植后复发并改善高危费城染色体阴性B细胞急性淋巴细胞白血病接受异基因造血干细胞移植患者的生存。

研究设计与样本

  • 多中心观察性队列研究,自5个中心纳入143例适合异基因造血干细胞移植的高危费城染色体阴性B细胞急性淋巴细胞白血病患者。
  • 儿童启发队列77例,成人队列66例,两组基线特征可比;143例中128例接受了异基因造血干细胞移植。

主要发现

  • 3年无白血病生存率儿童启发队列72.2%(95%CI 60.8%-83.6%) vs 成人队列44.6%(95%CI 31.9%-57.3%),p=0.001。
  • 移植后3年累积复发率儿童启发队列25.9%(95%CI 15.8%-37.2%) vs 成人队列45.4%(95%CI 40.0%-57.9%),p=0.026;移植后至微小残留病阳性的时间两组明显不同。
  • 3年总生存率儿童启发队列75.3%(95%CI 64.9%-85.7%) vs 成人队列64.1%(95%CI 51.8%-76.4%),p=0.074。
  • 多因素分析中儿童启发方案为无白血病生存的预测因素(HR=2.540,95%CI 1.327-4.862,p=0.005)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This PASS-ALL study was designed to explore the effect of paediatric-inspired versus adult chemotherapy regimens on survival of adolescents and young adults (AYA) with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia (HR PH-ve B-cell ALL) eligible for allogeneic haematopoietic stem cell transplantation (allo-HSCT). The PASS-ALL study is a multicentre, observational cohort study, and 143 patients with HR B-cell PH-ve ALL were enrolled from five centres-77 patients allocated in the paediatric-inspired cohort and 66 in the adult cohort with comparable baseline characteristics. Of the 143 patients, 128 cases underwent allo-HSCT. Three-year leukaemia-free survival (LFS) in the paediatric-inspired cohort was 72.2% (95% CI 60.8%-83.6%) compared with 44.6% (95% CI 31.9%-57.3%; p = 0.001). Furthermore, time-to-positive minimal residual disease (TTP-MRD) post-HSCT was marked different, 3-year cumulative incidence of relapse was 25.9% (95% CI 15.8%-37.2%) in paediatric cohort and 45.4% (95% CI 40.0%-57.9%) in adult cohort (p = 0.026). Finally, the 3-year OS rate was 75.3% (95% CI 64.9%-85.7%) for the paediatric-inspired cohort and 64.1% (95% CI 51.8%-76.4%) for the adult cohort (p = 0.074). On a multivariate analysis, paediatric-inspired regimen is a predictive factor for LFS (HR = 2.540, 95% CI 1.327-4.862, p = 0.005). Collectively, our data suggest that paediatric-inspired chemotherapy pre-HSCT results in deeper and durable MRD response reduces relapse post-HSCT and improves survival in HR B-cell PH-ve ALL patients with allo-HSCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wang Z, Fan Z, Wu Z, et al. PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2023. PMID: 38050437. doi:10.1111/bjh.19223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。